Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: An observational study

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Inoue, Kana ^a   Maeda, Norikazu ^a   Fujishima, Yuya ^a   Fukuda, Shiro ^a   Nagao, Hirofumi ^a   Yamaoka, Masaya ^a   Hirata, Ayumu ^a   Nishizawa, Hitoshi ^a   Funahashi, Tohru ^a   Shimomura, Iichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Diabetes; Eating behavior; Glucagon like peptide 1; Liraglutide; Metabolic syndrome; Obesity

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIDIABETIC AGENT; ASPARTATE AMINOTRANSFERASE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DIABETIC PATIENT; DISEASE DURATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN TREATMENT; JAPANESE (PEOPLE); LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTPATIENT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 84907429444     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-95     Document Type: Article

References (24)

1. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, Mullany EC, Biryukov S, Abbafati C, Abera SF, Abraham JP, Abu-Rmeileh NM, Achoki T, AlBuhairan FS, Alemu ZA, Alfonso R, Ali MK, Ali R, Guzman NA, Ammar W, Anwari P, Banerjee A, Barquera S, Basu S, Bennett DA, Bhutta Z, Blore J, Cabral N, Nonato IC, Chang JC, et al. Lancet 2014 384 766 781 10.1016/S0140-6736(14)60460-8 24880830
2. Obesity and diabetes in the developing world-a growing challenge. Hossain P, Kawar B, El Nahas M, N Engl J Med 2007 356 213 215 10.1056/NEJMp068177 17229948
3. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB, JAMA 2009 301 2129 2140 10.1001/jama.2009.726 19470990
4. Adiponectin and metabolic syndrome. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I, Arterioscler Thromb Vasc Biol 2004 24 29 33 10.1161/01.ATV.0000099786.99623.EF 14551151
5. The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism. Holst JJ, Orskov C, Diabetes 2004 53 197 S204 10.2337/diabetes.53.suppl-3.S197 15561911
6. Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D, J Clin Endocrinol Metab 2009 94 1843 1852 10.1210/jc.2008-1296 19336511
7. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M, Diabetologia 2002 45 195 202 10.1007/s00125-001-0719-z 11935150
8. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B, LEAD-3 (Mono) Study Group, Diabetes Obes Metab 2011 13 348 356 10.1111/j.1463-1326.2010.01356.x 21205128
9. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Nauck M, Frid A, Hermansen K, Thomsen AB, During M, Shah N, Tankova T, Mitha I, Matthews DR, Diabetes Obes Metab 2013 15 204 212 10.1111/dom.12012 22985213
10. Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes. Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, Hiuge-Shimizu A, Okita K, Imagawa A, Funahashi T, Shimomura I, Cardiovasc Diabetol 2011 10 109 10.1186/1475-2840-10-109 22132774
11. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, Kozawa J, Yasuda T, Okita K, Imagawa A, Funahashi T, Shimomura I, Cardiovasc Diabetol 2012 11 107 10.1186/1475-2840-11-107 22973968
12. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB, Diabetes 2007 56 8 15 10.2337/db06-0565 17192459
13. Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs. Raun K, von Voss P, Knudsen LB, Obesity (Silver Spring) 2007 15 1710 1716 10.1038/oby.2007.204 17636089
14. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. Hunter K, Hölscher C, BMC Neurosci 2012 13 33 10.1186/1471-2202-13-33 22443187
15. Cardiovascular actions of incretin-based therapies. Ussher JR, Drucker DJ, Circ Res 2014 114 1788 1803 10.1161/CIRCRESAHA.114.301958 24855202
16. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C, Doran S, Jax T, Zdravkovic M, Chapman IM, Diabetes Res Clin Pract 2012 97 258 266 10.1016/j.diabres.2012.02.016 22446097
17. Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients. Fadini GP, Simioni N, Frison V, Dal Pos M, Bettio M, Rocchini P, Avogaro A, Acta Diabetol 2013 50 943 949 10.1007/s00592-013-0489-3 23754673
18. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H, Diabetes 2010 59 1030 1037 10.2337/db09-1694 20068138
19. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Rizzo M, Chandalia M, Patti AM, Di Bartolo V, Rizvi AA, Montalto G, Abate N, Cardiovasc Diabetol 2014 13 49 10.1186/1475-2840-13-49 24559258
20. Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagon-like peptide-1-based therapies. Chilton R, Wyatt J, Nandish S, Oliveros R, Lujan M, Am J Med 2011 124 35 S53 10.1016/j.amjmed.2010.11.004 21194579
21. The effect of glucagon-like peptide 1 on cardiovascular risk. Sivertsen J, Rosenmeier J, Holst JJ, Vilsbøll T, Nat Rev Cardiol 2012 9 209 222 10.1038/nrcardio.2011.211 22290234
22. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Drucker DJ, Diabetes 2013 62 3316 3323 10.2337/db13-0822 23818527
23. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, Hill JO, Brancati FL, Peters A, Wagenknecht L, Look AHEAD Research Group, Diabetes Care 2011 34 1481 1486 10.2337/dc10-2415 21593294
24. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG, Curr Med Res Opin 2008 24 275 286 18053320